Payment overview · 2025
General Payments
$548.66
30 reported records · 9 companies
Healthcare provider profile · identity verified
Jesse Vincent Gabriel, MD
Allopathic & Osteopathic Physicians|Family Medicine · PITTSBURGH, PA · NPI 1760782601
Verified facts
What the public records show
CMS Open Payments records show Jesse Vincent Gabriel, MD received $548.66 in general payments during 2025 across 30 reported records.
Novo Nordisk Inc accounted for 47.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $261.70 | 47.7% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.27 | 15.7% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.37 | 8.6% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $47.09 | 8.6% | 2 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $32.00 | 5.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.35 | 4.1% | 1 | 2025 |
| WATERMARK MEDICAL, INC. | Unresolved — no canonical attribution shown | $18.64 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.72 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.52 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $548.66 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $92.24 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $86.27 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $86.27 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $78.17 | 7 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $47.09 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $47.09 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.70 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.26 | 2 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $32.00 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| ARES 620 UNICORDER Normalized: ares 620 unicorder |
Device | WATERMARK MEDICAL, INC. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 352 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 226 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 44 |
| Losartan Potassium | Losartan Potassium | 179 | 42 |
| Lisinopril | Lisinopril | 174 | 44 |
| Potassium Chloride | Potassium Chloride | 139 | 30 |
| Donepezil Hcl | Donepezil Hcl | 133 | 26 |
| Sertraline Hcl | Sertraline Hcl | 127 | 32 |
| Eliquis | Apixaban | 124 | 34 |
| Gabapentin | Gabapentin | 119 | 32 |
| Furosemide | Furosemide | 107 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 25 |
| Omeprazole | Omeprazole | 94 | 26 |
| Simvastatin | Simvastatin | 92 | 24 |
| Trazodone Hcl | Trazodone Hcl | 91 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 21 |
| Famotidine | Famotidine | 85 | 21 |
| Mirtazapine | Mirtazapine | 85 | 20 |
| Buspirone Hcl | Buspirone Hcl | 84 | 17 |
| Memantine Hcl | Memantine Hcl | 78 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 21 |
| Montelukast Sodium | Montelukast Sodium | 51 | 12 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Meloxicam | Meloxicam | 48 | suppressed |
| Metformin Hcl | Metformin Hcl | 47 | 15 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Allopurinol | Allopurinol | 43 | 11 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Atenolol | Atenolol | 38 | 11 |
| Azithromycin | Azithromycin | 38 | 36 |
| Lorazepam | Lorazepam | 38 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 37 | 14 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 31 |
| Tramadol Hcl | Tramadol Hcl | 33 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 28 | 11 |
| Valsartan | Valsartan | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 23 |
| Anastrozole | Anastrozole | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 12 |
| Finasteride | Finasteride | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $548.66 · 30 records | Novo Nordisk Inc | ABRYSVO, ARES 620 UNICORDER, AREXVY, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, TELEPATCH CARDIAC MONITOR, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error